Adherence to tuberculosis treatment
- Lee B Reichman, MD, MPH
Lee B Reichman, MD, MPH
- Professor of Medicine
- New Jersey Medical School
- Alfred A Lardizabal, MD
Alfred A Lardizabal, MD
- Associate Professor of Medicine
- New Jersey Medical School
Tuberculosis (TB) is nearly always curable if patients are treated with effective, uninterrupted antituberculous therapy. Adherence to treatment is critical for cure of individual patients, controlling spread of infection and minimizing the development of drug resistance [1,2].
Issues related to treatment adherence will be reviewed here. The clinical approach to treatment of TB is discussed in detail separately. (See "Treatment of pulmonary tuberculosis in HIV-negative patients" and "Treatment of pulmonary tuberculosis in the HIV-infected patient".)
CHALLENGES OF ADHERENCE
Incomplete adherence to treatment has been identified as the most serious problem in tuberculosis control , and a major obstacle to the elimination of the disease . In one retrospective study including 184 patients with TB in New York City (nearly half of whom were nonadherent), the nonadherent patients took longer to convert to negative culture results (254 versus 64 days), were more likely to acquire drug resistance (relative risk 5.6), and required longer treatment regimens (560 versus 324 days) .
Treatment adherence can be particularly challenging in the setting of tuberculosis; the duration of treatment is long (usually six months or longer), combination therapy is required, and side effects may be unpleasant.
Factors affecting adherence — Successful treatment among patients with TB may be influenced by several factors:
- Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279:943.
- Chaulet, P. Treatment of tuberculosis: Case holding until cure. WHO/TB/83.141. Geneva, World Health Organization, 1983.
- Addington WW. Patient compliance: the most serious remaining problem in the control of tuberculosis in the United States. Chest 1979; 76:741.
- Mason JO. Opportunities for the elimination of tuberculosis. Am Rev Respir Dis 1986; 134:201.
- Pablos-Méndez A, Knirsch CA, Barr RG, et al. Nonadherence in tuberculosis treatment: predictors and consequences in New York City. Am J Med 1997; 102:164.
- Sbarbaro JA. The patient-physician relationship: compliance revisited. Ann Allergy 1990; 64:325.
- Miller B, Snider DE Jr. Physician noncompliance with tuberculosis preventive measures. Am Rev Respir Dis 1987; 135:1.
- Volmink J, Garner P. Systematic review of randomised controlled trials of strategies to promote adherence to tuberculosis treatment. BMJ 1997; 315:1403.
- American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.
- Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA 1995; 274:945.
- Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330:1179.
- Porco TC, Oh P, Flood JM. Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006. Clin Infect Dis 2013; 56:761.
- Zwarenstein M, Schoeman JH, Vundule C, et al. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998; 352:1340.
- Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet 2001; 357:664.
- Hill AR, Manikal VM, Riska PF. Effectiveness of directly observed therapy (DOT) for tuberculosis: a review of multinational experience reported in 1990-2000. Medicine (Baltimore) 2002; 81:179.
- Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med 1995; 122:951.
- Buchanan RJ. Compliance with tuberculosis drug regimens: incentives and enablers offered by public health departments. Am J Public Health 1997; 87:2014.
- Salomon N, Perlman DC, Rubenstein A, et al. Implementation of universal directly observed therapy at a New York City hospital and evaluation of an out-patient directly observed therapy program. Int J Tuberc Lung Dis 1997; 1:397.
- Burman WJ, Cohn DL, Rietmeijer CA, et al. Noncompliance with directly observed therapy for tuberculosis. Epidemiology and effect on the outcome of treatment. Chest 1997; 111:1168.
- Gasner MR, Maw KL, Feldman GE, et al. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med 1999; 340:359.
- Singleton L, Turner M, Haskal R, et al. Long-term hospitalization for tuberculosis control. Experience with a medical-psychosocial inpatient unit. JAMA 1997; 278:838.
- Oscherwitz T, Tulsky JP, Roger S, et al. Detention of persistently nonadherent patients with tuberculosis. JAMA 1997; 278:843.
- Lerner BH. Catching patients: tuberculosis and detention in the 1990s. Chest 1999; 115:236.